REMEDY is focused on bringing LIFE SAVING TREATMENT to millions of people affected by acute CENTRAL NERVOUS SYSTEM CONDITIONS - including stroke, traumatic brain injury, and spinal cord injury, as well as other ischemic injuries.


Founded in 2005 and based in New York, Remedy is a privately-held, clinical stage pharmaceutical company focused on the development and commercialization of a revolutionary, breakthrough drug, CIRARA™, for treating acute central nervous system conditions - where there are inadequate or no approved existing therapies. These include stroke (ischemic and hemorrhagic), traumatic brain injury, and spinal cord injury, as well as other ischemic injuries.


CIRARA is a patented intravenous formulation that can be delivered bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology1.

Acute central nervous system disorders. Including stroke, traumatic brain injury, and spinal cord injury, as well as other ischemic injuries -- the common thread in all these indications is that the sooner and the more effective the treatment possible, the better the outcome.

Sadly, little effective treatment is currently available for many of these conditions, and where therapies do exist, the majority of patients arrive at hospital outside the short window needed to receive such care – thus, an abundant opportunity exists for CIRARA to medically intervene, expand the critical time window for treatment, lower mortality, improve patient quality of life, and reduce overall healthcare costs.

We strive to achieve this goal every day.


The people at Remedy are passionate and committed to the mission of making a difference in the lives of patients facing acute life-threatening conditions.

Remedy’s executive management team has a proven track record in building successful multi-national companies.

David M. Geliebter, Executive Chairman, Co-Founder

David M. Geliebter, Executive Chairman, Co-Founder David is a co-founder of Remedy Pharmaceuticals. A serial entrepreneur, he has over 50 years of experience successfully starting and growing several businesses. David founded and ran the Carson Group, a global financial information and advisory company, which was sold to Thomson Corporation in 2000. He was also a founding principal and President of Evolution Capital, a healthcare investment banking firm. Prior to that, David founded Harvard Capital, a financial communications company that was acquired by WPP Group in 1986. David is the Managing Partner of Carrot Capital Healthcare Ventures and founder and board member of Critical Diagnostics, a diagnostics company focused on cardiac disease. David is a past winner of the Ernst & Young Entrepreneur of the Year Award. CLICK HERE TO EMAIL DAVID

Sven M. Jacobson, MBA, CEO, Co-Founder

Sven is a co-founder of Remedy Pharmaceuticals. He has been the CEO of Remedy since 2007 and serves on the company’s board of directors. He is the inventor of CIRARA’s formulation and the company’s MPD technology. Sven has over 20 years of senior management experience. Sven is a Partner at Carrot Capital Healthcare Ventures and co-founder and board member of Critical Diagnostics, a diagnostics company focused on cardiac disease. Sven was also a co-founder of Access Scientific, which was acquired by Endeavour Capital, as well as Cure Therapeutics, and St. Camillus Medical. He has experience in the neurocritical care, neurology, cardiovascular, orthopedic, and vascular access fields. Sven’s international experience includes prior executive management positions at Leisureplanet (Belgium) and Rennies Travel and Financial Services Group (South Africa), and current board membership of Critical Diagnostics Ltd. (Ireland). Sven received his Bachelor of Science Engineering (BSc Eng) and MBA degrees from the University of the Witwatersrand in Johannesburg, South Africa. CLICK HERE TO EMAIL SVEN

Richard I. Steinhart, MBA, CPA, CFO

Richard is a veteran of the biotechnology and medical device industries, with nearly 30 years of experience. Earlier in his career he was employed by MELA Sciences, Inc. (NASDAQ:MELA) as the Company’s Senior Vice President, Finance and Chief Financial Officer, Treasurer and Secretary. Prior to joining MELA, Richard was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies. Prior to that, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Richard’s other experience includes seven years at CW Group, Inc., one of the country’s first venture capital firms focused exclusively on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. He began his career at Price Waterhouse, now known as PricewaterhouseCoopers. He holds B.B.A. and M.B.A degrees from Pace University and is a Certified Public Accountant (inactive). CLICK HERE TO EMAIL RICHARD

Ann C. Tunstall, PhD, Vice President of Regulatory And Clinical Operations

Ann has worked as a regulatory and clinical professional in the healthcare industry for more than 25 years, identifying and implementing effective regulatory and clinical development strategies for novel and repositioned pharmaceuticals and combination products. Her experience covers a wide range of therapeutic areas, with a focus on neurological indications. She started her career as a research and development scientist. After several years she moved into regulatory and clinical consulting, and worked for a number of Washington, DC-based healthcare consulting companies, most recently for SciLucent LLC. In this role she has routinely prepared successful pre-IND, IND and marketing applications to the U.S. Food and Drug Administration and other regulatory authorities, as well as clinical protocols, study reports, and other regulatory and study-related documents. She has assisted companies in directing and managing clinical trial programs from initial Phase 1 through pivotal Phase 3 trials. Ann has also served as the director of a Midwest clinical research institute and Director of Clinical Development for a healthcare start-up. Ann has a Ph.D. in Biomedical Engineering from the University of Texas Southwestern Medical Center, an M.S. in Material Science from Duke University, and a B.S. in Biomedical Engineering from Duke University.

Enda F. Anatole, Office Assistant

Enda was graduated with a Bachelors Degree in Human Resource Management from Baruch College in 2013. Prior to joining Remedy she performed administrative duties for Carrot Capital (an investor in Remedy) and Andrew Davidson and Company.


In addition to board members David M. Geliebter and Sven M. Jacobson (see management above), the board includes Kurt Landgraf, along with board observers Eric A. Potts and Frederick Jones, as well as Charles A. Mele, as special advisor to the board.

Kurt Landgraf

Kurt Landgraf has over 45 years of commercial experience including 30 years in the pharmaceutical industry in the United States, Europe, Middle East, and Africa. He worked at DuPont from 1980 to 2000 as Director Marketing Services, DuPont Pharmaceuticals, Director Medical Products Division Europe Middle East Africa, Director DuPont Pharmaceuticals and Radiopharmaceuticals Divisions, Executive Vice President DuPont /Merck Pharmaceuticals, President and CEO of DuPont /Merck Pharmaceuticals. He was then asked to return to the DuPont Company, first as Chief Financial Officer then Executive Vice President, Chief Operating Officer and Chairman of DuPont Europe. After leaving DuPont Kurt was President and CEO of the Educational Testing Service in Princeton New Jersey until 2014. He began his career in 1970 at Johnson and Johnson as a sales representative, and then spent six years at The Upjohn Company in market research and new product planning. Kurt is a member of the Board of Directors at the Corning and Louisiana Pacific Corporations. Previously he was a member of the Board at NDC Health Care, IKON Office Solutions, NanoDynamics LLC and AAI Pharmaceuticals.

J. Marc Simard, M.D., Ph.D. (Scientific Founder)

Dr. Simard is Professor of Neurosurgery, Pathology and Physiology at the University of Maryland School of Medicine. He is a board-certified clinical neurosurgeon with an active practice, specializing in vascular neurosurgery, which includes the surgery and management of patients with stroke, subarachnoid hemorrhage and other vascular lesions of the brain. He also serves as chief of Neurological Surgery at the Baltimore Veteran's Affairs Medical Center. Dr. Simard is an experienced investigative scientist who is responsible for the original discovery of the Sur1-Trpm4 channel (previously, the Sur1-regulated NCCa-ATP channel), and for initiating the work showing involvement of the channel in acute diseases of the CNS. Dr. Simard’s work on the Sur1-Trpm4 channel has led to the award of 21 US and international patents, as well as filings for several others.

Eric A. Potts, M.D.

Dr. Potts is a principal of ING Pharma, LLC, an investor in Remedy Pharmaceuticals. Dr. Potts is a neurosurgeon with Goodman Campbell Brain and Spine in Indianapolis, IN.  He serves as Assistant Professor of Neurological Surgery at Indiana University School of Medicine.  He attended college at the University of Pennsylvania, completed medical school at Indiana University School of Medicine, and completed his residency in neurological surgery at the University of Maryland Medical Systems.  While he was a resident in Baltimore, he conducted research in Dr. Marc Simard’s laboratory with voltage-gated channels in astrocytes. Dr. Potts is affiliated with multiple hospitals in the Indianapolis’ area, including Richard L. Roudebush Veterans Affairs Medical Center and St. Vincent Carmel Hospital, where he is Vice Chairman, Department of Neurosurgery. Dr. Potts’ other hospital affiliations include Community Hospitals of Indiana and University Health Methodist Hospital.

Frederick “Rick” Jones, M.D.

Rick shares responsibility for the day-to-day operations of Broadview Ventures. Broadview Ventures is an investor in Remedy Pharmaceuticals. Broadview’s mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures. Prior to joining Broadview, Rick founded Spordiff Therapeutics, which is developing a small molecule to prevent C. difficile infection. Previously, Rick was CEO of Anchor Therapeutics, a venture-backed company developing a platform of lipidated peptides targeting intractable GPCR targets. Rick also held positions with Devgen, BioRexis and Wyeth Pharmaceuticals. Early in his career, Dr. Jones practiced internal medicine, most recently as Assistant Professor in the University of Pennsylvania health system. Rick earned his undergraduate, medical and MBA degrees from the University of Pennsylvania.

Charles A. Mele

Charles Mele is a special advisor to Remedy. Mr. Mele currently serves as Special Counsel to the Chairman of WebMD Health Corp. He served as Executive Vice President and General Counsel of HLTH Corporation and its predecessors until its merger into WebMD in 2009. HLTH was the parent company of WebMD, Emdeon Business Services, Medical Manager, ViPs, Inc. and Porex Technologies Corp. Prior to that, from 1986 to 2001 Mr. Mele served as the Executive Vice President and General Counsel of Medical Manager Corp. and its predecessor, Synetic, Inc. He was also Executive Vice President and General Counsel of Medco Containment Services, Inc. from its inception until its acquisition by Merck in 1993. He has served as a Director of Medco, Synetic, CareInsite, Medical Manager, Group One Software and COMNET Corp.

Edgar S. Woolard

Edgar S. Woolard is a special advisor to Remedy. Mr. Woolard is the former Chairman and Chief Executive Officer of DuPont. He spent four decades with DuPont, before retiring in 1997. As highlighted in Fortune magazine’s 2012 article, “50 Greatest Business Decisions of All Time,” it was Ed, as newly appointed Chairman of the Board of Apple who, in 1997, spearheaded the decision by the board to fire then-CEO Gil Amelio and bring Steve Jobs back to the company, thus saving Apple from likely bankruptcy. Mr. Woolard is a former director of the New York Stock Exchange Inc., Telex Communications Inc., Citigroup Inc., IBM, Bell Atlantic Delaware, and Apple. He is also a former Chairman of the Business Council.


The Company has a network of gifted scientists, doctors and health professionals with decades of hands-on experience in bringing revolutionary, life-saving drugs to market.

Eugene D. Means, M.D. FAAN, Medical and Clinical Trials Consultant

Dr. Means has more than 30 years in the CNS field, having held the positions of Group Director of CNS at Upjohn, now part of Pfizer (NYSE:PFE), as well as Executive Director of CNS and Medical Leader of Emerging Products at Astra Merck, now AstraZeneca (NYSE:AZN). Dr. Means was Head of Clinical Research and Acting Head of Drug Development of AstraZeneca in the U.S., and more recently Executive Director of Field Medical.

Gregory J. del Zoppo, M.D.

Dr. del Zoppo is a Professor of Medicine, Division of Hematology and Adjunct Professor of Neurology at the University of Washington School of Medicine. Acute therapy, prevention and management of ischemic stroke and thrombolysis are Dr. del Zoppo’s special interests. Further, he is interested in the pathology of cerebral ischemia and TIA, and in the mechanisms of the development of intracranial hemorrhage. Among awards received are the Javits Neuroscience Investigator Award of the NINDS, election to the Association of American Physicians and to the American Neurological Association, and the chairmanship and participation in review for the NIH and for the Deutsche Forschungsgemeinschaft. Dr. del Zoppo has served as principal investigator of clinical trials in acute stroke treatments, chaired a number of committees for the NIH/ NINDS, participated in ASA and AHA activities. He is a member of the Stroke Council of the American Stroke Association and has authored and co-authored more than 100 publications on cerebro- and cardiovascular diseases and has contributed to several books about the pathophysiology, diagnosis and management of stroke.

Thomas W. MacAllister, JD, PhD, Special Advisor

Tom is a pharmaceutical executive with a PhD in molecular biology and over 25 years of experience including business development, drug discovery, preclinical and clinical development, regulatory strategy, intellectual property acquisition and enforcement, as well as commercialization. He is an attorney licensed to practice law in the Commonwealth of Virginia, the District of Columbia and before the United States Patent & Trademark Office.


CLINTREX team members have extensive experience in all aspects of the development process for new drugs and devices. Members of the CLINTREX team have served as Director of the Division of Neurologic Products (formerly the Neuropharmacologic Drug Products division) of the FDA, Chairman of the Peripheral and Central Nervous System advisory Committee of the FDA, presented to and consulted with the FDA, EMA, Health Canada, and the Japanese Ministry of Health & Welfare on dozens of occasions, and led pivotal clinical trials that resulted in the approval of multiple medical and surgical treatments.


Kevin N. Sheth, M.D.

Dr. Sheth is the founding chief of the Division of Neurocritical Care and Emergency Neurology and Chief of Clinical Research for the Department of Neurology at Yale New Haven Hospital, where he is also the fellowship director in neurocritical care. Dr. Sheth is a nationally recognized clinical and translational scientist and has directed a number of multicenter studies testing novel therapies. He is the winner of the prestigious Robert Siekert Award from the American Heart Association, and his research has been supported by the NIH, American Academy of Neurology, American Heart Association (AHA), US Army, and the Passano Foundation. He has led the initial AHA working group for large stroke and swelling. Dr. Sheth is the author of over 70 publications in critical care neurology and stroke. He serves on six editorial boards including Stroke, Neurocritical Care, and Neurosurgery and has served on study sections for the NIH, AHA, FDA and NASA. Dr. Sheth was the principal investigator (PI) of GAMES-Pilot study and is the co-PI of GAMES-RP.

W. Taylor Kimberly, M.D., Ph.D.

Dr. Kimberly is the Associate Director of the Massachusetts General Hospital Neuroscience Intensive Care Unit and an Assistant Professor of Neurology at Harvard Medical School. An alumnus of the Harvard Clinical Investigator Training Program, Dr. Kimberly’s research interests focus on the development of novel blood-based and neuroimaging biomarkers of acute brain injury and cerebral edema. Using a variety of techniques, a major goal of the Kimberly lab is to apply patient-oriented tools to improve the translation of novel therapeutic targets for stroke and better understand the mechanisms involved in cerebral ischemia. His laboratory has developed a panel of surrogate markers for ischemic brain edema. Dr. Kimberly was site PI on the GAMES-Pilot study. Together with Dr. Kevin Sheth, Dr. Kimberly serves as co-lead investigator for the GAMES-RP phase 2 trial.



Remedy Pharmaceuticals, Inc.
122 West 27th Street, 10th Floor
New York, NY 10001

1. Measured Phase Dosing. 1